Table 1 Clinical trials included trastuzumab pertuzumab pre-treated metastatic breast cancer population. The second part of the table reported the data from the two phases III trials EMILIA and TH3RESA included in the analysis as comparators
First author name (Trial) | Year | Previous treatment | T-DM1 line | PFS months | 95%CI | Patients N | 1-year PFS % patients |
|---|---|---|---|---|---|---|---|
Dzimitrowicz et al. [5] | 2016 | TP + CHT or ET | 2nd and further | 4 | 2,7—5,1 | 78 | NA |
Conte et al. [8] | 2019 | TP TXT | 2nd-line | 6,3 | 4,8—7,7 | 77 | 28 |
Urruticoechea et al. [14] (CLEOPATRA) (PHEREXA) | 2017 | TP TXT | 2nd and further | 7,1 | 0—44 | 32 | NA |
2017 | TPC | 2nd and further | 4,2 | 0—22 | 43 | NA | |
Fabi et al. [9] | 2017 | TP TXT | 2nd-line | 5 | 4,3—5,7 | 34 | 48 |
Noda-Narita et al. [10] | 2019 | TP TXT | 2nd and further | 2,8 | 1,7—4,8 | 18 | 12 |
Vici et al. [11] | 2017 | TP TXT | 2nd and further | 4 | 2—7 | 47 | 13,2 |
Lupichuk et al. [12] | 2019 | TP TXT | 2nd and further | 5,5 | 55 | 22 | |
Battisti et al. [13] | 2020 | TP TXT | 2nd and further | 8,7 | 6,6—11,3 | 37 | NA |
Del prete et al. [] | 2020 | TP TXT | 2nd | 10,5 | 8,6—12,7 | 135 | 47 |
Huober et al. (PERNETTA) [6] | 2018 | TP | 2nd | 7,1 | 4,3—11,9 | 59 | 30 |
2018 | TP TXT | 2nd | 5,3 | 4—10,3 | 42 | 32 | |
Comparator Phase III trial | |||||||
Krop et al. (EMILIA) [4] | 2012 | T TXT | 2nd | 9,6 | 0,55 – 0,77 | 495 | 40 |